Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 7

1.

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC, Jänne PA.

Science. 2007 May 18;316(5827):1039-43.

2.

Targeting the MET gene for the treatment of non-small-cell lung cancer.

Gelsomino F, Facchinetti F, Haspinger ER, Garassino MC, Trusolino L, De Braud F, Tiseo M.

Crit Rev Oncol Hematol. 2014 Feb;89(2):284-99. doi: 10.1016/j.critrevonc.2013.11.006. Review.

PMID:
24355409
3.

Targeting of erbB3 receptor to overcome resistance in cancer treatment.

Ma J, Lyu H, Huang J, Liu B.

Mol Cancer. 2014 May 8;13:105. doi: 10.1186/1476-4598-13-105. Review.

4.

MET as a possible target for non-small-cell lung cancer.

Sadiq AA, Salgia R.

J Clin Oncol. 2013 Mar 10;31(8):1089-96. doi: 10.1200/JCO.2012.43.9422. Review.

5.

HER3 as a Therapeutic Target in Cancer.

Karachaliou N, Lazzari C, Verlicchi A, Sosa AE, Rosell R.

BioDrugs. 2017 Feb;31(1):63-73. doi: 10.1007/s40259-016-0205-2. Review.

PMID:
28000159
6.

The promise of anti-ErbB3 monoclonals as new cancer therapeutics.

Aurisicchio L, Marra E, Roscilli G, Mancini R, Ciliberto G.

Oncotarget. 2012 Aug;3(8):744-58. Review.

7.

MET pathway as a therapeutic target.

Kim ES, Salgia R.

J Thorac Oncol. 2009 Apr;4(4):444-7. doi: 10.1097/JTO.0b013e31819d6f91. Review.

Supplemental Content

Support Center